SIHUAN PHARM (00460) has reported its interim results for the six months ended June 30, 2026, showcasing a substantial jump in profitability. The group recorded a total revenue of RMB 1.161 billion, marking a 1.3% increase year-on-year, while profit attributable to shareholders surged 119% to RMB 225 million, with basic earnings per share reaching 2.49 cents.

The revenue shift was primarily driven by its medical aesthetics and innovative drug operations. During the period, revenue from the medical aesthetics segment climbed approximately 18.5% to RMB 693 million, up from RMB 585 million in the prior corresponding period. The segment's steady performance was underpinned by robust growth in the core product Letybo (botulinum toxin), alongside sustained volume expansion in regenerative aesthetic products, including collagen stimulators and dermal fillers, as well as functional aesthetic offerings. These factors solidified medical aesthetics as a key profit contributor for the group.

Revenue from innovative drugs and other pharmaceuticals soared roughly 349.1% year-on-year to RMB 261 million, compared to RMB 58.2 million in the first half of 2025. The commercialization of its innovative drug portfolio continued to advance, with several approved products delivering strong progress in both commercial rollout and international expansion. This drove a significant uptick in combined revenue, and unlike the net loss recorded in the prior period, the segment posted a slight net profit during the current half.

Throughout the first half of 2026, the group has steadfastly adhered to its medium-to-long-term dual-engine development strategy focused on "medical aesthetics plus innovative drugs." Multiple operational milestones were achieved across business segments, leading to sustained improvements in the overall business fundamentals. The profitability enhancement logic has continued to materialize, while the group concurrently advances AI-driven R&D empowerment, global expansion initiatives, and multi-tiered capital market operations, further solidifying its foundation for long-term value growth.